期刊文献+

SHNH法和NHS-MAG_3法标记的^(99m)Tc-寡聚核苷酸的比较

A Comparison on Radiochemical Behavior and Biological Property of Antisense Oligonucleotide Labeled with Technetium-99m by Two Methods:NHS-MAG_3 versus SHNHP
下载PDF
导出
摘要 比较研究采用联肼尼克酰胺(Hydrazino Nicotinamide Derivative,SHNH)法和N-羟基琥珀酰胺基S-乙酰巯基乙酰三氨基乙酸(N-hydroxysuccinimidyl S-acetylmercaptoacetyltriglycline,NHS-MAG3)法以99mTc标记反义寡聚核苷酸(Antisense Oligonucleotide,ASON)的标记物的放射化学和生物学特性。合成SHNH和NHS-MAG3后,分别以SHNH和NHS-MAG3为双功能络(螯)合剂,用99mTc标记ASON;比较标记物99mTc-SHNH ASON和99mTc-MAG3-ASON的体内外稳定性、兔血浆蛋白结合、正常BALB/C小鼠体内分布及结肠腺癌HT29细胞摄取的情况。结果显示,采用NHS-MAG3法标记的标记物99mTc-MAG3-ASON的标记率和稳定性明显高于SHNH法标记的标记物99mTc-SHNH-ASON(P<0.05)、血浆蛋白结合率显著低于99mTc-SHNH-ASON(P<0.05);99mTc-MAG3-ASON在血液、心脏、胃、肠的分布显著低于99mTc-SHNH-ASON(P<0.05),而在肝、脾的分布略低于99mTc-SHNH-ASON(P>0.05),但在肾的分布显著高于99mTc-SHNH-ASON(P<0.05);99mTc-MAG3-ASON的HT29细胞摄取率显著高于99mTc-SHNH-ASON(P<0.05)。因此,采用NHS-MAG3法的标记物99mTc-MAG3-ASON的放射化学和生物学特性明显优于SHNH法的标记物99mTc-SHNH-ASON。 This study was undertaken to explore and compare the radiochemical behavior and biological property of antisense oligonucleotide (ASON) labeled with Technetium-99m using two methods:N-hydroxysuccinimidyl S-acetylmercaptoacetyltriglycline(NHS-MAG3) versus hydrazino nicotinamide derivative (SHNH).After SHNH and NHS-MAG3 were synthesized, ASON was labeled with Technetium-99m using SHNH and NHS-MAG3 as a bifunctional chelator, separately. The stability in vivo and in vitro, the combination with plasma albumen o...
出处 《生物医学工程学杂志》 EI CAS CSCD 北大核心 2008年第4期889-893,902,共6页 Journal of Biomedical Engineering
基金 国家自然科学基金资助项目(39870200) 卫生部临床重点学科资助项目(20013547)
关键词 反义寡聚核苷酸 联肼尼克酰胺 N-羟基琥珀酰胺基-S-乙酰巯基乙酰三氨基乙酸 标记 特性 Antisense oligonucleotide (ASON) Hydrazino nicotinamide derivative (SHNH) N-hydroxysuccinimidyl S-acetylmercaptoacetyltriglycline (NHS-MAG3) Labeling Property
  • 相关文献

参考文献10

  • 1Gano L,Patricio L,Marques E,et al.Human polyclonal i m-munoglobulinlabeled with technetium-99mvia NHS-MAG3:a com-parison of radiochemical behavior and biological efficacy with other labeling methods[].Nuclear Medicine and Biology.1998 被引量:1
  • 2Ou XH,Tan TZ,He L,et al.Antitumor effects of radioiodinated antisense oligonuclide mediated by VIP receptor[].Cancer Gene Therapy.2005 被引量:1
  • 3Ginobbi P,Geiser TA,Ombres D,et al.Folic acid-polylysine carri-er i mproves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma(M14)cells[].Anticancer Research.1997 被引量:1
  • 4Wessels BW,Rogus RD.Radionuclide selection and model absorbed does calculations for radiolabeled tumor associated antibodies[].Medical Physics.1984 被引量:1
  • 5HNATOWICH DJ,,VIRZI F,DOHERTY PW.DTPA-Coupled Antibodies Labeled With Yttrium-90[].The Journal of Nuclear Medicine.1985 被引量:1
  • 6Anderson-Berg WT,Squire RA,Strand M.Specific radioimmunotherapy using 90 Y-labeled maonoclonal antibody in erythroleukemic mice[].Cancer Research.1987 被引量:1
  • 7Hnatowich DJ,Mardirossian G,Fogarasi M,et al.Comparative Properties of a Technetium-99m-Labeled Single Stranded Natural DNA and a Phosphorothioate Derivative in Vitro and in Mice[].Journal of Pharmacology and Experimental Therapeutics.1996 被引量:1
  • 8Winnard P Jr,Chang F,Rusckowski M,et al.Preparation and use of NHS-MAG3 for technetium-99m labeling of DNA[].Nuclear Medicine and Biology.1997 被引量:1
  • 9Wagner RW.Gene inhibition using antisense oligodeoxynucleotides[].Nature.1994 被引量:1
  • 10Juliano RL,Akhtar A.Liposomes as a drug delivery system for antisense oligonucleotides[].Antisense Research and Development.1992 被引量:1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部